Journal of Epidemiology and Public Health
ISSN: 3065-9078 | DOI: 10.64030/3065-9078
Mehdi Alem, Sara Nejjaria, Assiya Benamar, Mounir Belcadi Abbassi, Maryam Msakem, Diango Keita, Lamiae Amaadour, Karima Oualla, Zineb Benbrahim, Samia Arifi, Touria Bouhafa and Nawfel Mellas
Background Ewing’s sarcoma (ES) arising from the pleura is an exceedingly rare entity, accounting for fewer than 2% of all ES cases. Its rarity and non-specific clinical presentation frequently result in diagnostic delays and therapeutic challenges.
Case Presentations We report two young female patients with histologically confirmed pleural ES managed at our institution. The first, a 25-yearold woman, presented with a large locally advanced left pleural ES and received six cycles of VIDE (vincristine, ifosfamide, doxorubicin, etoposide) neoadjuvant chemotherapy, achieving an initial response followed by metastatic progression requiring second-line gemcitabine-docetaxel. The second, an 18-year-old woman, presented with a locally advanced right latero-thoracic
Conclusion soft-tissue ES with pleural involvement and was treated with three cycles of VDC-IE (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide), achieving a 73% partial response; surgical resection was declined and she was referred for consolidative radiotherapy. Pleural ES is an aggressive malignancy requiring multidisciplinary management. Immunohistochemical confirmation (CD99 positivity) and cytogenetic analysis are essential for diagnosis. Multimodal treatment including chemotherapy, surgery, and radiotherapy remains the cornerstone of management. Our cases highlight the rarity of this tumor, the importance of early diagnosis, and the significant therapeutic challenges posed by locally advanced disease.